Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2019

Open Access 01-12-2019 | Porphyrias | Case report

Porphyria cutanea tarda: a case report

Authors: Hanife Usta Atmaca, Feray Akbas

Published in: Journal of Medical Case Reports | Issue 1/2019

Login to get access

Abstract

Background

The porphyrias are a rare group of metabolic disorders that can either be inherited or acquired. Along the heme biosynthetic pathway, porphyrias can manifest with neurovisceral and/or cutaneous symptoms, depending on the defective enzyme. Porphyria cutanea tarda, the most common type of porphyria worldwide, is caused by a deficiency of uroporphyrinogen decarboxylase, a crucial enzyme in heme biosynthesis, which results in an accumulation of photosensitive byproducts, such as uroporphyrinogen, which leads to the fragility and blistering of sun-exposed skin.
Porphyria cutanea tarda is a condition that affects the liver and skin by reduction and inhibition of uroporphyrinogen decarboxylase enzyme in erythrocytes. Areas of skin that are exposed to the sun can generate blisters, hyperpigmentation, and, sometimes, lesions that heal leaving a scar or keratosis. Liver damage might present in a wide range of ways from liver function test abnormalities to hepatocellular carcinoma. The toxic effect of iron plays a role in liver damage pathogenesis.

Case presentation

A 59-year-old Turkish man presented with hyperpigmented skin lesions, fatigue, and elevated ferritin level and liver function tests. He was diagnosed as having porphyria cutanea tarda after a clinical investigation and treated with phlebotomy.

Conclusion

Porphyria cutanea tarda is a rare condition of the liver but it must be remembered in a differential diagnosis of liver disease with typical skin involvement to decrease morbidity and health costs with early treatment.
Literature
1.
go back to reference Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006;135(3):281–92.CrossRef Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006;135(3):281–92.CrossRef
2.
go back to reference Farrag MS, Mikula I, Richard E, Saudek V, De Verneuil H, Martásek P. Hepatoerythropoietic Porphyria Caused by a Novel Homoallelic Mutation in Uroporphyrinogen Decarboxylase Gene in Egyptian Patients. Folia Biol (Praha). 2015;61(6):219–26. Farrag MS, Mikula I, Richard E, Saudek V, De Verneuil H, Martásek P. Hepatoerythropoietic Porphyria Caused by a Novel Homoallelic Mutation in Uroporphyrinogen Decarboxylase Gene in Egyptian Patients. Folia Biol (Praha). 2015;61(6):219–26.
3.
go back to reference Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of Heme Biosynthesis: X-Linked Sideroblastic Anemia and the Porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease, vol. 2. New York: McGraw–Hill; 2001. p. 2991–3062. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of Heme Biosynthesis: X-Linked Sideroblastic Anemia and the Porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease, vol. 2. New York: McGraw–Hill; 2001. p. 2991–3062.
4.
go back to reference Chan OT, Tsai N, Wong RL, Izumi AK. The additive effects of hepatitis C infection and end-stage renal disease in porphyria cutanea tarda. Cutis. 2006;78(6):397–400.PubMed Chan OT, Tsai N, Wong RL, Izumi AK. The additive effects of hepatitis C infection and end-stage renal disease in porphyria cutanea tarda. Cutis. 2006;78(6):397–400.PubMed
5.
go back to reference Frank J, Poblete-Gutierrez P. Porphyria cutanea tarda--when skin meets liver. Best Pract Res Clin Gastroenterol. 2010;24(5):735–45.CrossRef Frank J, Poblete-Gutierrez P. Porphyria cutanea tarda--when skin meets liver. Best Pract Res Clin Gastroenterol. 2010;24(5):735–45.CrossRef
6.
go back to reference Lim HW. Role of viral infection in porphyria cutanea tarda. Photodermatol Photoimmunol Photomed. 1997;13(3):75–7.CrossRef Lim HW. Role of viral infection in porphyria cutanea tarda. Photodermatol Photoimmunol Photomed. 1997;13(3):75–7.CrossRef
7.
go back to reference Sams H, Kiripolsky MG, Bhat L, Stricklin GP. Porphyria cutanea tarda, hepatitis C, alcoholism, and hemochromatosis: a case report and review of the literature. Cutis. 2004;73(3):188–90.PubMed Sams H, Kiripolsky MG, Bhat L, Stricklin GP. Porphyria cutanea tarda, hepatitis C, alcoholism, and hemochromatosis: a case report and review of the literature. Cutis. 2004;73(3):188–90.PubMed
8.
go back to reference Elder GH. Porphyria cutanea tarda and related disorders (Chapter 88). In: Kadish KM, Smith K, Guilard R, editors. Porphyrin Handbook, Part II, vol. 14. San Diego: Academic Press; 2003. p. 67–92.CrossRef Elder GH. Porphyria cutanea tarda and related disorders (Chapter 88). In: Kadish KM, Smith K, Guilard R, editors. Porphyrin Handbook, Part II, vol. 14. San Diego: Academic Press; 2003. p. 67–92.CrossRef
9.
go back to reference Wickliffe JK, Abdel-Rahman SZ, Lee C, Kormos-Hallberg C, Sood G, Rondelli CM, Grady JJ, Desnick RJ, Anderson KE. CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med. 2011;17(3–4):241–7.PubMed Wickliffe JK, Abdel-Rahman SZ, Lee C, Kormos-Hallberg C, Sood G, Rondelli CM, Grady JJ, Desnick RJ, Anderson KE. CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med. 2011;17(3–4):241–7.PubMed
10.
go back to reference Wahlin S, Floderus Y, Stål P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med. 2011;269(3):278–88.CrossRef Wahlin S, Floderus Y, Stål P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med. 2011;269(3):278–88.CrossRef
11.
12.
go back to reference Can C, Nigogosyan G. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide. JAMA. 1963;183:88–91.PubMed Can C, Nigogosyan G. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide. JAMA. 1963;183:88–91.PubMed
13.
go back to reference Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol. 2008;84(2):450–62.CrossRef Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol. 2008;84(2):450–62.CrossRef
14.
go back to reference Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Nat I Acad Sci USA. 2007;104:5079–84.CrossRef Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Nat I Acad Sci USA. 2007;104:5079–84.CrossRef
15.
go back to reference Bleasel NR, Varigos GA. Porphyria cutanea tarda. Australas J Dermatol. 2000;41(4):197–206.CrossRef Bleasel NR, Varigos GA. Porphyria cutanea tarda. Australas J Dermatol. 2000;41(4):197–206.CrossRef
16.
go back to reference Young LC. Porphyria cutanea tarda associated with Cys282Tyr mutation in HFE gene in hereditary hemochromatosis: a case report and review of the literature. Cutis. 2007;80:415–8.PubMed Young LC. Porphyria cutanea tarda associated with Cys282Tyr mutation in HFE gene in hereditary hemochromatosis: a case report and review of the literature. Cutis. 2007;80:415–8.PubMed
17.
go back to reference Egger NG, Goeger DE, Payne DA, et al. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci. 2002;47:419–26.CrossRef Egger NG, Goeger DE, Payne DA, et al. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci. 2002;47:419–26.CrossRef
18.
go back to reference Ratnaike S, Blake D, Campbell D, Cowen P, Varigos G. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by vene section. Australas J Dermatol. 1988;29(1):3–8.CrossRef Ratnaike S, Blake D, Campbell D, Cowen P, Varigos G. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by vene section. Australas J Dermatol. 1988;29(1):3–8.CrossRef
19.
go back to reference Rocchi E, Gibertini P, Cassanelli M, Pietrangelo A, Borghi A, Ventura E. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med. 1986;107(1):36–42.PubMed Rocchi E, Gibertini P, Cassanelli M, Pietrangelo A, Borghi A, Ventura E. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med. 1986;107(1):36–42.PubMed
20.
go back to reference Malina L, Chlumský J. A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. Acta Derm Venereol. 1981;61(4):346–50.PubMed Malina L, Chlumský J. A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. Acta Derm Venereol. 1981;61(4):346–50.PubMed
21.
go back to reference Kordac V, Semrádová M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol. 1974;90(1):95–100.CrossRef Kordac V, Semrádová M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol. 1974;90(1):95–100.CrossRef
22.
go back to reference Wolff C, Armas R, Krause P, Parraguez A, RamónSoto J. Treatment of porphyria cutanea tarda with chloroquine and its effect on associated liver disease: retrospective analysis. Rev Med Chil. 1996;124(4):456–60.PubMed Wolff C, Armas R, Krause P, Parraguez A, RamónSoto J. Treatment of porphyria cutanea tarda with chloroquine and its effect on associated liver disease: retrospective analysis. Rev Med Chil. 1996;124(4):456–60.PubMed
23.
go back to reference Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10:1402–9.CrossRef Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10:1402–9.CrossRef
Metadata
Title
Porphyria cutanea tarda: a case report
Authors
Hanife Usta Atmaca
Feray Akbas
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2019
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-018-1956-9

Other articles of this Issue 1/2019

Journal of Medical Case Reports 1/2019 Go to the issue